BioToxTech Co

BioToxTech Co Net Tangible Assets

The Net Tangible Assets of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 40.16 B KRW. In the previous year, Net Tangible Assets was 38.42 B KRW — a change of 4.53% (higher).

Net Tangible Assets

40.16 BKRW

YoY

4.53%

Last updated:

Net Tangible Assets of BioToxTech Co is 2025 40.16 B KRW. Net Tangible Assets of BioToxTech Co was 2024 38.42 B KRW. It decreases by 4.53% higher compared to the previous year.

The BioToxTech Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
21.17 B KRW
Jan 1, 2019
29.97 B KRW
Jan 1, 2020
32.21 B KRW
Jan 1, 2021
39.61 B KRW
Jan 1, 2022
42.75 B KRW
Jan 1, 2023
50.11 B KRW
Jan 1, 2024
38.42 B KRW
Jan 1, 2025
40.16 B KRW
The BioToxTech Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
40.16 BKRW+4.53%
38.42 BKRW-23.34%
50.11 BKRW+17.22%
42.75 BKRW+7.94%
39.61 BKRW+22.98%
32.21 BKRW+7.47%
29.97 BKRW+41.58%
21.17 BKRW+62.48%
13.03 BKRW-42.82%
22.78 BKRW+11.13%
20.50 BKRW-10.00%
22.78 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Net Tangible Assets of BioToxTech Co is 40.16 B KRW in 2025.

Net Tangible Assets of BioToxTech Co changed from 38.42 B KRW to 40.16 B KRW, representing a 4.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioToxTech Co

All Key Metrics — BioToxTech Co